MBG453 with hypomethylating agents in AML and high-risk MDS

preview_player
Показать описание
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, details the results of the Phase Ib multicenter, open-label study of the anti-TIM-3 antibody sabatolimab in combination with hypomethylating agents in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Andrew Wei
  3. Institution: Alfred Hospital and Monash University
  4. Event: VJVirtual
  5. Event: ESH AL 2020
  6. Format: Interview
Рекомендации по теме
MBG453 with hypomethylating 0:07:28

MBG453 with hypomethylating agents in AML and high-risk MDS

Uma Borate: Evaluating 0:04:32

Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Anti-TIM-3 antibody sabatolimab 0:06:51

Anti-TIM-3 antibody sabatolimab + hypomethylating agents for high-risk MDS & AML

State of the 0:01:16

State of the art: MDS

Combination of Oral 0:03:58

Combination of Oral Rigosertib and Azacitidine in Patients with MDS

How is higher-risk 0:02:50

How is higher-risk MDS treated?

The current challenges 0:00:59

The current challenges facing high-risk MDS treatment

Novel therapies for 0:01:41

Novel therapies for high-risk MDS

What new treatments 0:08:40

What new treatments are available for high-risk MDS? What does this mean for patients?

Sabatolimab plus HMAs 0:04:47

Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML

Immune Checkpoint Inhibition 0:33:10

Immune Checkpoint Inhibition in Myeloid Malignancies

Dr. Amer Zeidan: 0:40:49

Dr. Amer Zeidan: “Immune checkpoint inhibition for AML and MDS: Is there a way forward?”

Update on immunotherapy 0:01:18

Update on immunotherapy in MDS

Future treatment priorities 0:01:21

Future treatment priorities for high-risk MDS

The Therapeutic Revolution 1:00:07

The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapy

What is MDS? 1:27:40

What is MDS? How Do We Determine Prognosis?

Focus on Understanding 1:31:47

Focus on Understanding Clinical Trials and How to Identify the Right One for You

Dr. Sekeres on 0:01:48

Dr. Sekeres on Staging Low- Versus High-Risk MDS

MDS: treating high 0:03:15

MDS: treating high and low-risk disease

Therapy-related MDS 0:01:58

Therapy-related MDS

Next questions in 0:06:58

Next questions in AML

Myelodysplastic Syndrome 1:39:54

Myelodysplastic Syndrome

Pevonedistat with azacitidine 0:01:47

Pevonedistat with azacitidine for high-risk MDS

Evaluating the Magrolimab-Based 0:04:19

Evaluating the Magrolimab-Based Triplet Combination in High-Risk AML